Multi-Vials Segment to Dominate Europe Low Molecular Weight Heparin Market during 2019–2028

According to a new market research study on “Europe Low Molecular Weight Heparin Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Packaging, Application, and End User,” is expected to reach US$ 2,021.53 million by 2028 from US$ 1,315.04 million in 2021. The market is estimated to grow at a CAGR of 6.3% from 2021 to 2028. Advantages of low molecular weight heparin over unfractionated heparin is the major factor driving the growth of the Europe low molecular weight heparin market. However, adverse effects of low molecular weight heparin during treatment may hinder the growth of Europe low molecular weight heparin market. The report provides trends prevailing in the Europe low molecular weight heparin market along with the drivers and restraints pertaining to the market growth.

The COVID-19 outbreak curve continues to fluctuate, moving from bad to worse in Europe. This is irrespective of the fact that the European countries vary significantly in size, population, natural resources, economy, and political stability. Governments of European countries imposed various restrictions to control the effects of the outbreak in 2020 and early 2021. This led to disruptions, limitations, challenges, and changes in each sector of every industry. The COVID-19 pandemic also impacted the performance of the low molecular weight heparin (LMWH) industry. After the onset of the COVID-19 pandemic, the adoption of strict social containment measures and reorganization of healthcare systems helped them cope with the enormous increase in the number of patients.

The Europe low molecular weight heparin market is segmented into product type, packaging, application, end user and country. The Europe low molecular weight heparin market, based on product type, has been segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. The Europe low molecular weight heparin market based on packaging is segmented into multi-vials and prefilled syringes. In 2021, the multi-vials segment held the largest share of the market. The Europe low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. The Europe low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into U.K., Germany, France, Italy, Spain, and rest of Europe. Germany held the largest share of the Europe low molecular weight heparin market in 2021. 

Abbott, Aspen Holdings, B. Braun Medical Inc., Dr. Reddy's Laboratories, LEO Pharma A/S, Novartis, Pfizer Inc., Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the Europe Low Molecular Weight Heparin Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Aspen gets unsolicited offers for pharma ingredient unit. The approaches are for operations almost exclusively in Europe and make both chemicals and the anticoagulant drug heparin.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com